How does ATTB.F's PB Ratio compare to its peers?

Insufficient data to calculate ATTB.F's Price-To-Book Ratio vs. peers for valuation analysis.

How does ATTB.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

Insufficient data to calculate ATTB.F's Price-To-Book Ratio vs. industry for valuation analysis.

What is ATTB.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate ATTB.F's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of ATTB.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate ATTB.F's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

ATTB.F Stock Overview

Operates as a life sciences and biotechnology company in Canada. More details

ATTB.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($476)

Latest financial reports are more than a year old

My Notes

Capture your thoughts, links and company narrative

Abattis Bioceuticals Corp. Competitors

Clever Leaves Holdings

OTCPK:CLVR

US$350.0

BZAM

OTCPK:BZAM.F

US$270.0

Juva Life

OTCPK:JUVA.F

US$164.0

Ampio Pharmaceuticals

OTCPK:AMPE

US$3.0k

Price History & Performance

Summary of share price highs, lows and changes for Abattis Bioceuticals
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.00013
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0%
5 Year Change	-99.99%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ATTB.F	US Pharmaceuticals	US Market
7D	0%	0.4%	3.8%
1Y	0%	1.4%	24.4%

Return vs Industry: ATTB.F matched the US Pharmaceuticals industry which returned 0.2% over the past year.

Return vs Market: ATTB.F underperformed the US Market which returned 23.7% over the past year.

Price Volatility

Is ATTB.F's price volatile compared to industry and market?
ATTB.F volatility
ATTB.F Average Weekly Movement	0%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	6.5%
10% most volatile stocks in US Market	18.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine ATTB.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	n/a	n/a	www.abattis.com

Abattis Bioceuticals Corp. operates as a life sciences and biotechnology company in Canada. The company develops and licenses natural health products, medicines, extractions, and ingredients for the biological, nutraceutical, bioceutical, and cosmetic markets. It also provides Comfort, a cannabinoid enhanced nutraceutical for pain and inflammation; and Health-Canada licensed services for the cannabis industry.

Abattis Bioceuticals Corp. Fundamentals Summary

How do Abattis Bioceuticals's earnings and revenue compare to its market cap?
ATTB.F fundamental statistics
Market cap	US$476.00
Earnings (TTM)	-US$2.11m
Revenue (TTM)	US$247.26k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ATTB.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATTB.F income statement (TTM)
Revenue	CA$356.88k
Cost of Revenue	CA$115.54k
Gross Profit	CA$241.34k
Other Expenses	CA$3.28m
Earnings	-CA$3.04m

Last Reported Earnings

Sep 30, 2019

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ATTB.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/21 05:46
End of Day Share Price	2025/01/17 00:00
Earnings	2019/09/30
Annual Earnings	2019/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abattis Bioceuticals Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Siddharth Rajeev	Fundamental Research Corp.